MX376200B - Formulacion en polvo nasal para el tratamiento de hipoglicemia. - Google Patents

Formulacion en polvo nasal para el tratamiento de hipoglicemia.

Info

Publication number
MX376200B
MX376200B MX2017010572A MX2017010572A MX376200B MX 376200 B MX376200 B MX 376200B MX 2017010572 A MX2017010572 A MX 2017010572A MX 2017010572 A MX2017010572 A MX 2017010572A MX 376200 B MX376200 B MX 376200B
Authority
MX
Mexico
Prior art keywords
powder formulation
treatment
hypoglycemia
nasal powder
provides
Prior art date
Application number
MX2017010572A
Other languages
English (en)
Other versions
MX2017010572A (es
Inventor
Claude A Piche
Betsbrugge Jo Jan Filip Van
Sankaram B Mantripragada
Original Assignee
Amphastar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55538593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX376200(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amphastar Pharmaceuticals Inc filed Critical Amphastar Pharmaceuticals Inc
Publication of MX2017010572A publication Critical patent/MX2017010572A/es
Publication of MX376200B publication Critical patent/MX376200B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición en polvo, caracterizada porque comprende glucagón (SEQ ID NO: 1), un fosfolípido, y ß-coclodextroma, en donde la proporción de glucagón a fosfolípido a ß-ciclodextrina es 1:1:8 en peso.
MX2017010572A 2015-02-17 2016-02-16 Formulacion en polvo nasal para el tratamiento de hipoglicemia. MX376200B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562117031P 2015-02-17 2015-02-17
PCT/US2016/018003 WO2016133863A1 (en) 2015-02-17 2016-02-16 Nasal powder formulation for treatment of hypoglycemia

Publications (2)

Publication Number Publication Date
MX2017010572A MX2017010572A (es) 2017-12-07
MX376200B true MX376200B (es) 2025-03-07

Family

ID=55538593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010572A MX376200B (es) 2015-02-17 2016-02-16 Formulacion en polvo nasal para el tratamiento de hipoglicemia.

Country Status (41)

Country Link
US (3) US10213487B2 (es)
EP (3) EP3673900B1 (es)
JP (3) JP6522144B2 (es)
KR (1) KR102121443B1 (es)
CN (1) CN107278154B (es)
AU (2) AU2016220235B2 (es)
BR (1) BR112017014994B1 (es)
CA (1) CA2975562C (es)
CL (1) CL2017002031A1 (es)
CO (1) CO2017008148A2 (es)
CR (1) CR20170373A (es)
CY (1) CY1122716T1 (es)
DK (1) DK3258919T4 (es)
DO (1) DOP2017000179A (es)
EA (1) EA034820B1 (es)
EC (1) ECSP17053843A (es)
ES (1) ES2775498T5 (es)
FI (1) FI3258919T4 (es)
GT (1) GT201700179A (es)
HR (1) HRP20200222T4 (es)
HU (1) HUE049413T2 (es)
IL (1) IL253273B (es)
LT (1) LT3258919T (es)
MA (3) MA52253A (es)
MD (1) MD3258919T3 (es)
MX (1) MX376200B (es)
MY (1) MY175669A (es)
NZ (1) NZ734035A (es)
PE (1) PE20171334A1 (es)
PH (1) PH12017501486A1 (es)
PL (1) PL3258919T5 (es)
PT (1) PT3258919T (es)
RS (1) RS59918B2 (es)
SA (1) SA517382068B1 (es)
SG (1) SG11201705640PA (es)
SI (1) SI3258919T2 (es)
SV (1) SV2017005515A (es)
TN (1) TN2017000349A1 (es)
UA (1) UA121874C2 (es)
WO (1) WO2016133863A1 (es)
ZA (2) ZA201704944B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52253A (fr) 2015-02-17 2021-02-17 Lilly Co Eli Formulation de poudre nasale pour le traitement de l'hypoglycémie
JP2019504684A (ja) 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器
US11013873B2 (en) * 2017-01-06 2021-05-25 HealthPartners Institite Methods for treating patients with impaired awareness of hypoglycemia
DK3881861T3 (da) 2017-06-16 2024-09-09 Zealand Pharma As Doseringsregimer for indgivelse af glukagonlignende peptid-2- (GLP-2)-analoger
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
JP7334145B2 (ja) 2017-08-20 2023-08-28 ネイサス ファーマ リミテッド 鼻腔内送達用乾燥粉末組成物
WO2019060761A1 (en) 2017-09-21 2019-03-28 The Scripps Research Institute NEW THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINO-SINUSITIS
TWI771669B (zh) * 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
KR20220154110A (ko) 2020-03-16 2022-11-21 질랜드 파마 에이/에스 글루카곤 유사체의 액체 제형
EP3962455B1 (en) 2020-05-18 2022-08-31 Orexo AB New pharmaceutical composition for drug delivery
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2023094826A1 (en) 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising adrenaline
CN119454909B (zh) * 2025-01-13 2025-04-08 上海世领制药有限公司 经鼻粘膜给药的胰高血糖素样肽-1受体激动剂的制剂组合物、制备方法、用途及鼻施用器

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
EP0308181A1 (en) 1987-09-14 1989-03-22 Novo Nordisk A/S Trans-mucosal delivery formulations and a method for preparation thereof
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE69913113T2 (de) 1998-03-10 2004-08-26 Valois S.A.S. Behälter, verfahren zur befüllung dieses behälter und abgabevorrichtung für das im behälter enthaltene pulver
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
AU2612599A (en) 1998-03-13 1999-10-11 Novo Nordisk A/S Stabilized aqueous peptide solutions
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
US6522144B2 (en) 2000-12-22 2003-02-18 Ge Medical Systems Global Technology Company, Llc RF shielding method and apparatus for an open MRI system
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
MXPA06003830A (es) 2003-10-09 2006-07-03 Bioactis Ltd Aparato para abastecer medicina pulverizada para la cavidad nasal.
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
BRPI0620586A2 (pt) 2005-12-02 2011-11-16 Nastech Pharm Co formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
WO2011117417A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
US9216196B2 (en) 2011-05-27 2015-12-22 Jose Schafik Colazo Handal Drink for the rapid replacement of calcium ions in the blood stream
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
SG11201403377QA (en) 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
CN104470569B (zh) 2012-06-28 2018-04-27 美国政府(由卫生和人类服务部的部长所代表) 用于疫苗和其它治疗试剂的鼻干粉递送系统
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Binding between a ski and a ski boot
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
MA52253A (fr) * 2015-02-17 2021-02-17 Lilly Co Eli Formulation de poudre nasale pour le traitement de l'hypoglycémie

Also Published As

Publication number Publication date
DOP2017000179A (es) 2017-08-31
PL3258919T5 (pl) 2023-02-27
EP3258919B1 (en) 2020-01-15
DK3258919T4 (da) 2022-11-21
AU2021203035B2 (en) 2023-07-13
ZA201901241B (en) 2020-10-28
EA201791560A1 (ru) 2018-02-28
US12370241B2 (en) 2025-07-29
ES2775498T3 (es) 2020-07-27
LT3258919T (lt) 2020-02-25
AU2021203035A1 (en) 2021-06-10
HUE049413T2 (hu) 2020-09-28
SG11201705640PA (en) 2017-08-30
SA517382068B1 (ar) 2020-10-26
AU2016220235B2 (en) 2021-04-29
MA52253A (fr) 2021-02-17
EP3673899C0 (en) 2025-06-25
EP3673900B1 (en) 2025-06-25
US20230302093A1 (en) 2023-09-28
MX2017010572A (es) 2017-12-07
BR112017014994B1 (pt) 2023-12-19
JP7362687B2 (ja) 2023-10-17
CA2975562C (en) 2020-04-28
BR112017014994A2 (pt) 2018-03-20
SV2017005515A (es) 2018-08-27
KR20170103934A (ko) 2017-09-13
RS59918B2 (sr) 2023-01-31
US20180000904A1 (en) 2018-01-04
CL2017002031A1 (es) 2018-03-23
EP3258919B2 (en) 2022-11-09
KR102121443B1 (ko) 2020-06-10
MA41547B1 (fr) 2020-04-30
PT3258919T (pt) 2020-03-26
PH12017501486A1 (en) 2018-01-15
JP7094242B2 (ja) 2022-07-01
JP2021107418A (ja) 2021-07-29
EP3673900C0 (en) 2025-06-25
ECSP17053843A (es) 2017-11-30
NZ734035A (en) 2019-06-28
EP3673900A1 (en) 2020-07-01
EA034820B1 (ru) 2020-03-25
ES2775498T5 (es) 2023-01-31
CA2975562A1 (en) 2016-08-25
RS59918B1 (sr) 2020-03-31
SI3258919T2 (sl) 2023-01-31
CY1122716T1 (el) 2021-03-12
PL3258919T3 (pl) 2020-08-10
PE20171334A1 (es) 2017-09-13
FI3258919T4 (fi) 2023-02-09
ZA201704944B (en) 2021-05-26
CN107278154B (zh) 2021-04-09
EP3258919A1 (en) 2017-12-27
UA121874C2 (uk) 2020-08-10
EP3673899A1 (en) 2020-07-01
AU2016220235A1 (en) 2017-07-20
DK3258919T3 (da) 2020-03-23
US12226456B2 (en) 2025-02-18
CN107278154A (zh) 2017-10-20
GT201700179A (es) 2018-11-23
JP2019147817A (ja) 2019-09-05
JP2018507852A (ja) 2018-03-22
JP6522144B2 (ja) 2019-05-29
SI3258919T1 (sl) 2020-03-31
TN2017000349A1 (en) 2019-01-16
MA52252A (fr) 2021-02-17
MD3258919T3 (ro) 2023-04-30
HRP20200222T1 (hr) 2020-05-29
WO2016133863A1 (en) 2016-08-25
CO2017008148A2 (es) 2017-11-30
IL253273A0 (en) 2017-08-31
IL253273B (en) 2019-08-29
HRP20200222T4 (hr) 2022-12-23
CR20170373A (es) 2017-09-18
US10213487B2 (en) 2019-02-26
MD3258919T2 (ro) 2020-07-31
EP3673899B1 (en) 2025-06-25
US20190282666A1 (en) 2019-09-19
MY175669A (en) 2020-07-03

Similar Documents

Publication Publication Date Title
MX376200B (es) Formulacion en polvo nasal para el tratamiento de hipoglicemia.
IL287749A (en) Compositions for administering implantable drugs and methods of their use
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
MX378273B (es) Compuestos activos hacia bromodominios.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
GB201411465D0 (en) Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
GB2541571A (en) Pharmaceutical compositions
MX2020002693A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
IL251503A0 (en) Single-chain biphasic insulin analogs, preparations containing them and their uses
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
NZ728401A (en) High purity oritavancin and method of producing same
PH12017501979A1 (en) Pharmaceutical compound
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
GB201915641D0 (en) Glucose-responsive insulin analogs and methods of use thereof
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
EA201301341A1 (ru) Фармацевтическая композиция, обладающая панкреопротекторным действием, её применение для профилактики или лечения панкреатита и способ профилактики и лечения панкреатита
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.

Legal Events

Date Code Title Description
FG Grant or registration